Genetics & Genomics Frontiers — October 25, 2026
Prime Medicine has dosed the first patient with an in-body prime editing therapy for Wilson disease, marking a significant milestone for genetic treatments. Meanwhile, GeneDx is presenting a substantial body of research at the upcoming ASHG 2026 Annual Meeting, highlighting advances in rare disease diagnosis and genomic data utilization.
Genetics & Genomics Frontiers — October 25, 2026
Key Highlights
-
First In-Body Prime Editing Dose: Prime Medicine has successfully dosed the first patient with PM577A, a one-time in-body prime editing therapy designed to treat Wilson disease. Initial results from this trial are expected in 2027. This represents a shift toward direct in-body delivery of gene-editing tools, moving beyond ex vivo cell therapies.
Wilson disease gene therapy -
GeneDx at ASHG 2026: GeneDx announced the acceptance of 27 scientific abstracts for the American Society of Human Genetics (ASHG) 2026 Annual Meeting. The presentations will focus on the clinical adoption of genomic medicine, specifically leveraging exome and genome data to improve rare disease diagnosis.
GeneDx research presentation
Analysis
The most promising development this week is the initiation of the first in-body prime editing trial for Wilson disease. While CRISPR-based therapies like Casgevy have shown success in ex vivo settings (such as for Sickle Cell Disease), the ability to administer a one-time in-body therapy for a metabolic disorder like Wilson disease could significantly broaden the accessibility and applicability of gene editing. Prime editing, known for its precision and ability to make small, precise changes without creating double-strand breaks, is being tested here for its potential to correct the underlying genetic cause of Wilson disease directly in the liver.
What to Watch
- 2027 Clinical Data: The primary focus for the coming year will be the clinical results from Prime Medicine’s PM577A trial, expected in 2027. Safety and efficacy data from this first-in-human study will be critical for the future of in-body prime editing.
- ASHG 2026 Insights: The 27 abstracts presented by GeneDx at the ASHG 2026 Annual Meeting will provide insights into how genomic data is being integrated into clinical workflows for rare disease diagnosis.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
